Borderline ovarian tumors(BOTs) are the epithelial neoplasm which need to be differentiated from ovarian carcinomas as their presentation and management differs from each other. The important differentiating feature on histopathological examination is the absence of stromal invasion. Considering the degree of aggressiveness between epithelial ovarian carcinoma and benign ovarian neoplasms like cystadenoma, borderline neoplasms are closer to benign ovarian neoplasms as regards the clinical behavior. Surgery with intention of removal of all visible tumors is the most important pillar in treatment. Patients treated conservatively with fertility sparing surgery and good results with laparoscopic surgery has low recurrence rate which makes them successful options according to the circumstances. Overall prognosis of these tumors is good with survival rate more than 90% at 10 years in early stage borderline tumors but small percentage of patients with borderline neoplasms may show more aggressive form of the disease, and trials have been made to figure out the histological correlates that might predict for worse outcome. There is no added advantage of postoperative adjuvant chemotherapy or radiation in any stage especially with non-invasive component. Follow up is done by observation of the patient and any further intervention is kept reserved for recurrent disease.